Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Evaxion Biotech A/s

Clinical trials sponsored by Evaxion Biotech A/s, explained in plain language.

Evaxion Biotech A/S EVAX NASDAQ

Develops AI-driven immunotherapies for cancer and infectious diseases.

Trade on eToro (ad)

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Not yet finished but already full! 1

New combo shows promise against tough skin cancer

Disease control Ongoing

This phase 2 trial tests whether adding an experimental drug (EVX-01) to standard immunotherapy (pembrolizumab) can shrink tumors better than pembrolizumab alone in people with advanced melanoma that cannot be removed by surgery. Seventeen adults who have never received checkpoin…

Phase: PHASE2 • Sponsor: Evaxion Biotech A/S • Aim: Disease control

Last updated Jun 27, 2026 07:51 UTC